In most cases, we select targets that have been clinically or genetically validated, often by small molecule approaches, that were highly effective but failed due to severe toxicity. We use our unique platform, Abiprot™, to develop novel therapeutic antibodies against these targets while maintaining efficacy but with a completely different and improved toxicity profile. We also run two programs to address disruptive but scientifically compelling targets.
We are driven by curiosity and innovation to develop a solid portfolio based on asset-generation through our game-changing antibody platform, Abiprot™. Our approach is different: we start with patients and their needs for new medicines. Our goal is to generate novel medicines against any disease-modifying human protein target.
Read more
We are driven by curiosity and innovation to develop a solid portfolio based on asset-generation through our game-changing antibody platform, Abiprot™. Our approach is different: we start with patients and their needs for new medicines. Our goal is to generate novel medicines against any disease-modifying human protein target.
Read more
We are driven by curiosity and innovation to develop a solid portfolio based on asset-generation through our game-changing antibody platform, Abiprot™. Our approach is different: we start with patients and their needs for new medicines. Our goal is to generate novel medicines against any disease-modifying human protein target.
Read more
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam lacinia sapien in venenatis commodo. Nulla feugiat nulla dolor, quis pharetra ligula gravida in. Etiam viverra molestie nisl, in dignissim metus commodo vitae. Ut placerat quam sed lorem tincidunt rhoncus. Curabitur vel volutpat velit. Integer id nibh maximus dolor elementum lacinia. Nulla quis sollicitudin massa, vitae lobortis augue. Duis consectetur ac risus ac pellentesque. Duis vel augue massa.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam lacinia sapien in venenatis commodo. Nulla feugiat nulla dolor, quis pharetra ligula gravida in. Etiam viverra molestie nisl, in dignissim metus commodo vitae. Ut placerat quam sed lorem tincidunt rhoncus. Curabitur vel volutpat velit. Integer id nibh maximus dolor elementum lacinia. Nulla quis sollicitudin massa, vitae lobortis augue. Duis consectetur ac risus ac pellentesque. Duis vel augue massa.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam lacinia sapien in venenatis commodo. Nulla feugiat nulla dolor, quis pharetra ligula gravida in. Etiam viverra molestie nisl, in dignissim metus commodo vitae. Ut placerat quam sed lorem tincidunt rhoncus. Curabitur vel volutpat velit. Integer id nibh maximus dolor elementum lacinia. Nulla quis sollicitudin massa, vitae lobortis augue. Duis consectetur ac risus ac pellentesque. Duis vel augue massa.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam lacinia sapien in venenatis commodo. Nulla feugiat nulla dolor, quis pharetra ligula gravida in. Etiam viverra molestie nisl, in dignissim metus commodo vitae. Ut placerat quam sed lorem tincidunt rhoncus. Curabitur vel volutpat velit. Integer id nibh maximus dolor elementum lacinia. Nulla quis sollicitudin massa, vitae lobortis augue. Duis consectetur ac risus ac pellentesque. Duis vel augue massa.
We have a solid portfolio of promising future medicines and proprietary AbiprotTM technology, our evergreen antibody platform that can generate functional antibodies to any given disease-modifying target.
We have a solid portfolio of promising future medicines and proprietary AbiprotTM technology, our evergreen antibody platform that can generate functional antibodies to any given disease-modifying target.
